SLC5A2 and acute kidney injury: One large report from Taiwan analyzed data from more than 104,000 patients and found that, after a median follow-up of 2.5 years, patients using SGLT2 inhibitors had a lower incidence of AKI compared to those using DPP-4 inhibitors.